<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637283</url>
  </required_header>
  <id_info>
    <org_study_id>10008</org_study_id>
    <nct_id>NCT03637283</nct_id>
  </id_info>
  <brief_title>Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage</brief_title>
  <official_title>Feasibility Study of Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Anti-VEGF instead of intraoperative fan-shaped
      photocoagulation in BRVO combined with vitreous hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in best-corrected visual acuity (BCVA)</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed using the ETDRS protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in visual field</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed on Humphery(30-2 and 60-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chang from baseline in structure of retina</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed on Optical Coherence Tomography(OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chang from baseline in retinal neovascularization</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed on Fundus Fluorescein Angiography(FFA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anti-VEGF</condition>
  <condition>Branch Retinal Vein Occlusion</condition>
  <condition>Vitrectomy</condition>
  <arm_group>
    <arm_group_label>anti-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitreoretinal surgery combined with intraoperative anti-VEGF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fan-shaped photocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitreoretinal surgery combined with fan-shaped photocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anti-VEGF</intervention_name>
    <description>vitreoretinal surgery combined with intraoperative anti-VEGF</description>
    <arm_group_label>anti-VEGF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fan-shaped photocoagulation</intervention_name>
    <description>vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation</description>
    <arm_group_label>fan-shaped photocoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years old;

          2. BRVO is diagnosed

          3. Vitreous hemorrhage

          4. Vitreous hemorrhage combined with mild retinal fibrovascular proliferation (early
             fibrous vascular membrane, thin fibrous vascular membrane, loose retinal adhesion and
             intact local retinal structure)

        Exclusion Criteria:

          1. BRVO combined with severe retinal fibrovascular proliferation (long-term fibrovascular
             membrane, thick fibrous vascular membrane and tightly attached to the retina,
             deformation of local retinal, retinal tear or suspension of retinal vein )

          2. BRVO combined with retinal detachment

          3. Retinal veins are completely whitened

          4. iris neovascularization or neovascular glaucoma

          5. Combined glaucoma

          6. combined with other retinopathy

          7. Received anti-VEGF treatment within 3 months before surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Wei, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Wei, M.D</last_name>
    <phone>+86 15057551266</phone>
    <email>weiyongdoctor@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Lin, M.D</last_name>
    <phone>+86 13587560390</phone>
    <email>linweiysg@163.com</email>
  </overall_contact_backup>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Xiangtian Zhou</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

